<DOC>
	<DOCNO>NCT01314274</DOCNO>
	<brief_summary>In case series intranasal submucosal bevacizumab show reduce epistaxis patient suffer Hereditary Haemorrhagic Telangiectasia together KTP Laser therapy . The aim study evaluate effectiveness submucosal intranasal bevacizumab compare placebo randomize double blind trial setting .</brief_summary>
	<brief_title>Intranasal Submucosal Bevacizumab Epistaxis Hereditary Hemorrhagic Telangiectasia ( HHT )</brief_title>
	<detailed_description />
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Epistaxis</mesh_term>
	<mesh_term>Telangiectasia , Hereditary Hemorrhagic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Diagnosed stag HHT ( Shovlin et al 2000 ) Age 1880 Minimum 2 episode epistaxis/ week Ability willingness complete diary comply study requirement . Uncontrolled hypertension ( systolic blood pressure &gt; 150mmHg , diastolic blood pressure &gt; 90mmHg ) History thromboembolic event , include myocardial infarction cerebral vascular accident Malignancy upper respiratory tract within last year Recent ( &lt; 3 month ) plan surgery Proteinuria Nasal intervention ( Laser Cautery ) pretreatment phase Allergy local anesthetic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Epistaxis</keyword>
	<keyword>Osler</keyword>
	<keyword>Weber</keyword>
	<keyword>Rendu</keyword>
	<keyword>HHT</keyword>
	<keyword>Hereditary haemorrhagic telangiectasia</keyword>
</DOC>